Nav: Home

Current Pembrolizumab News and Events

Current Pembrolizumab News and Events, Pembrolizumab News Articles.
Sort By: Most Relevant | Most Viewed
Page 1 of 3 | 119 Results
Electronic nose can sniff out which lung cancer patients will respond to immunotherapy
An electronic nose that detects chemicals in the breath of lung cancer patients can identify with 85% accuracy those who will or will not respond to immunotherapy, according to new research published in the leading cancer journal Annals of Oncology. (2019-09-17)
KEYNOTE-024 three-year survival update
First line pembrolizumab monotherapy provides durable long-term overall survival benefit compared to chemotherapy, according to data presented today by Dr. (2019-09-10)
New KEYNOTE 021 data shows no association with tumor mutational burden
Researchers had previously reported data from the KEYNOTE 021 trial that showed antitumor activity for pembrolizumab plus platinum-based chemotherapy in untreated advanced nonsquamous non-small cell lung cancer patients. (2019-09-08)
Keynote 189: Tumor mutational burden not significantly associated with efficacy of pembrolizumab
Tumor mutational burden was not significantly associated with efficacy of pembrolizumab plus chemotherapy or placebo plus chemotherapy as first-line therapy for metastatic nonsquamous non-small cell lung cancer, according to research reported today by Dr. (2019-09-08)
New drug combination shows promising activity in non-small cell lung cancer patients
Patients with non-small cell lung cancer (NSCLC) now have more improved treatment options compared to standard of care with the addition of several new agents called immune-checkpoint inhibitors (ICI). (2019-08-27)
MSI detection via liquid biopsy shows high concordance with results from tissue samples
Incorporation of pan-cancer microsatellite instability (MSI) detection into the 74-gene panel Guardant360 liquid biopsy assay showed high concordance with matched tissue samples in nearly 1,000 patients. (2019-08-05)
Targeted therapy erdafitinib effective for patients with advanced bladder cancer and specific gene mutations
A Phase II clinical trial led by MD Anderson found that treatment with the FGFR inhibitor erdafitinib was effective in 40% of patients with metastatic bladder cancers marked by FGFR3 mutations. (2019-07-24)
Adding immunotherapy after initial treatment can benefit metastatic lung cancer patients
Treating metastatic non-small cell lung cancer (NSCLC) patients with the immunotherapy drug pembrolizumab after they've completed locally ablative therapy almost tripled the median progression-free survival (PFS) compared to the historical average. (2019-07-11)
Immunotherapy and HDAC inhibition are anti-cancer besties
Colorado study shows that adding HDAC inhibitor sensitized cancers to anti-PD1 therapy. (2019-06-24)
Immunotherapy drug found safe in treating cancer patients with HIV
The results of a study led by physicians at Fred Hutchinson Cancer Research Center showed that patients living with HIV and one of a variety of potentially deadly cancers could be safely treated with the immunotherapy drug pembrolizumab, also known by its brand name, KEYTRUDA. (2019-06-03)
Immunotherapy better than aggressive chemo as first-line treatment in head and neck cancer
Immunotherapy used with chemotherapy or on its own is a better first-line treatment for people with head and neck cancer that has returned than standard aggressive chemotherapy, new clinical trial results show. (2019-06-03)
Tumor mutations may predict response to immunotherapy
Center say they have found a potential explanation for the failures. (2019-05-07)
Biomarker may predict if immunotherapy is right choice for colorectal cancer patients
Foundational research could help metastatic colorectal cancer patients decide whether to choose immunotherapy or chemotherapy as a first treatment option. (2019-05-02)
Releasing an immune system brake could help patients with rare but fatal brain infection
The anti-cancer drug pembrolizumab has shown promise in slowing or stopping the progression of progressive multifocal leukoencephalopathy (PML), a typically fatal infection of the brain caused by the JC virus (JCV). (2019-04-10)
Studies give new insights on immunotherapy in elderly patients with advanced NSCLC
Two studies to be reported at ELCC 2019 provide new insights on the efficacy and safety of immunotherapy in elderly patients with advanced non-small-cell lung cancer (NSCLC), where information has previously been lacking despite being the age group most commonly affected. (2019-04-09)
Maintenance therapy with rucaparib shows clinical responses in a subgroup of patient with pancreatic cancer
Maintenance treatment with the PARP inhibitor rucaparib (Rubraca) was well tolerated and provided clinical responses among patients with advanced BRCA- or PALB2-mutated pancreatic cancer sensitive to platinum-based chemotherapy, according to results from an interim analysis of an ongoing phase II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-04-02)
Data from two KEYNOTE trials show pembrolizumab benefited patients with advanced SCLC
The anti-PD-1 monoclonal antibody pembrolizumab (Keytruda) showed promising antitumor activity with durable responses in patients with pretreated, advanced small cell lung cancer (SCLC), according to results from a pooled analysis of the two clinical trials, the phase 1b KEYNOTE-028 and the phase II KEYNOTE-158, presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-04-01)
HDAC inhibition may combat resistance to anti-PD-1 therapy in patients with melanoma
A combination of the experimental histone deacetylase (HDAC) inhibitor entinostat with the anti-PD-1 therapeutic pembrolizumab (Keytruda) showed clinical responses in patients with melanoma that had progressed on prior anti-PD-1 treatment, according to results from the ENCORE 601 phase Ib/II clinical trial presented at the AACR Annual Meeting 2019, March 29-April 3. (2019-04-01)
A single dose of a PD-1 inhibitor before surgery predicts outcomes in melanoma patients
A single dose of a PD-1 inhibitor before surgery for melanoma can put patients in remission. (2019-02-25)
New assay selects patients with lung cancer for treatment with immune checkpoint inhibitors
A report in The Journal of Molecular Diagnostics describes a novel and rapid approach for quantifying PD-L1 expression levels in tumors that requires only small amounts of tissue that can be collected using minimally invasive bronchoscopy techniques. (2019-02-13)
Immunotherapy can be effective in treating people with recurrent glioblastoma
A UCLA-led study suggests that for people with recurrent glioblastoma, administering an immunotherapy drug before surgery is more effective than using the drug afterward. (2019-02-11)
Immunotherapy drug used as 1st-line therapy for Merkel cell carcinoma improved survival
A multi-center phase II clinical trial investigating pembrolizumab as a first-line and programmed cell death-1 therapy in patients with advanced Merkel cell carcinoma reports lasting tumor control, generally manageable side effects and improved overall survival. (2019-02-07)
Immunotherapy appears better than chemotherapy for aggressive type of skin cancer
The first study of the immunotherapy drug pembrolizumab as the initial treatment for patients with a rare but aggressive form of skin cancer known as Merkel cell carcinoma reports better responses and longer survival than expected with conventional chemotherapy. (2019-02-07)
Advanced squamous cell carcinoma of the head and neck: Pembrolizumab prolongs survival
quamous cell carcinoma is one of the most common cancers of the skin and mucosa. (2019-01-17)
Researchers investigate how vial sizes can be optimized to reduce pharmaceutical wastage
Pharmaceuticals are often dosed according to patient weight or body size which means that a dose must be individually measured. (2018-12-05)
CNIO and Hospital 12 de Octubre extend effectiveness of immunotherapy to more lung cancer patients
Combining immunotherapy with chemotherapy in patients with metastatic squamous cell carcinoma 'significantly increases' the survival of patients. (2018-12-03)
Dana-Farber researchers report clinical trial results in treatment of leukemia & lymphoma
New results from clinical trials of immunotherapy and experimental targeted agents for patients with leukemia and lymphoma are being presented by Dana-Farber Cancer Institute researchers at the ASH Annual Meeting. (2018-12-02)
Immunotherapy keeps some advanced head and neck cancer patients alive for over three years
A new immunotherapy can greatly extend the lives of a proportion of people with advanced head and neck cancer, with some living for three years or more, a major new clinical trial reports. (2018-11-30)
Study: Immunotherapy better than chemotherapy for subtype of head and neck cancer
A randomized clinical trial involving 97 medical centers in 20 countries, including Moores Cancer Center at UC San Diego Health, found that treating patients with head and neck cancer with the immunotherapy drug pembrolizumab is more effective and less toxic than standard chemotherapy. (2018-11-30)
Immunotherapy effective as first-line treatment for advanced head and neck cancer
Immunotherapy on its own is better than aggressive chemotherapy as a first-line treatment for advanced head and neck cancer, according to surprising new data from a major phase III clinical trial. (2018-10-22)
Immunotherapy improves survival in metastatic or recurrent head and neck cancer
Immunotherapy with pembrolizumab improves survival in patients with head and neck cancer that has recurred or metastasised, according to late-breaking results from the KEYNOTE-048 study reported at the ESMO 2018 Congress in Munich. (2018-10-22)
Patient-partnered genomics study IDs immunotherapy as potential treatment for rare cancer
Angiosarcoma Project, a patient-partnered genomics study, identified immune checkpoint inhibition as a potential treatment option for patients with angiosarcomas of the head, face, neck, or scalp (HFNS), according to data presented at the fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. (2018-09-30)
Bacterial therapy tolerable, shows early promise in patients with advanced solid tumors
A phase I clinical trial investigating the use of bacterial Clostridium novyi-NT spores as an injectable monotherapy had manageable toxicities and showed early clinical efficacy in patients with treatment-refractory solid tumor malignancies, according to data presented at the Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival, held Sept. (2018-09-30)
Immunotherapy may be efficacious in patients with HIV-associated Kaposi's sarcoma
Among a small cohort of patients with HIV-associated Kaposi's sarcoma treated with immune checkpoint inhibitors, more than 65 percent had partial or complete remission. (2018-09-07)
Combination approach shows promise for beating advanced melanoma
A UCLA-led study has found that a treatment that uses a bacteria-like agent in combination with an immunotherapy drug could help some people with advanced melanoma, an aggressive form of skin cancer, live longer. (2018-08-28)
Retinoic acid may improve immune response against melanoma
University of Colorado Cancer Center clinical trial results describe a promising strategy to remove one of melanoma's most powerful defenses: By adding retinoic acid to standard-of-care treatment, researchers were able to turn off myeloid-derived suppressor cells (MDSCs) that turn off the immune system, leading to more immune system activity directed at melanoma. (2018-08-16)
Melanoma linked with CLL, close monitoring recommended
While studying a large group of individuals with chronic lymphocytic leukemia (CLL), a Wilmot Cancer Institute scientific team made an important discovery -- these patients had a sizable 600 percent higher risk of melanoma, the most dangerous form of skin cancer. (2018-08-09)
Cancer patients may experience delayed skin effects of anti-PD-1 therapy
Cancer patients receiving anti-PD-1 therapies who develop lesions, eczema, psoriasis, or other forms of auto-immune diseases affecting the skin may experience those adverse reactions on a delay -- sometimes even after treatment has concluded. (2018-07-18)
Otago researchers' discovery unlocks secrets behind cancer drug resistance
University of Otago research provides insights into an underlying mechanism that could explain why new cancer therapies to help treat metastatic melanoma do not always work on patients, paving the way for predicting which patients will benefit from certain drugs. (2018-06-29)
Gene testing could identify men with prostate cancer who may benefit from immunotherapy
Scientists have identified a pattern of genetic changes that could pick out men with advanced prostate cancer who are likely to benefit from immunotherapy. (2018-06-14)
Page 1 of 3 | 119 Results
   First   Previous   Next      Last   

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#534 Bacteria are Coming for Your OJ
What makes breakfast, breakfast? Well, according to every movie and TV show we've ever seen, a big glass of orange juice is basically required. But our morning grapefruit might be in danger. Why? Citrus greening, a bacteria carried by a bug, has infected 90% of the citrus groves in Florida. It's coming for your OJ. We'll talk with University of Maryland plant virologist Anne Simon about ways to stop the citrus killer, and with science writer and journalist Maryn McKenna about why throwing antibiotics at the problem is probably not the solution. Related links: A Review of the Citrus Greening...